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Background: G-protein-coupled estrogen receptor (GPER/GPR30) was reported to bind 17β-estradiol (E2), tamoxifen,
and ICI 182,780 (fulvestrant) and promotes activation of epidermal growth factor receptor (EGFR)-mediated signaling in
breast, endometrial and thyroid cancer cells. Although lung adenocarcinomas express estrogen receptors α and β
(ERα and ERβ), the expression of GPER in lung cancer has not been investigated. The purpose of this study was
to examine the expression of GPER in lung cancer.
Methods: The expression patterns of GPER in various lung cancer lines and lung tumors were investigated
using standard quantitative real time PCR (at mRNA levels), Western blot and immunohistochemistry (IHC)
methods (at protein levels). The expression of GPER was scored and the pairwise comparisons (cancer vs
adjacent tissues as well as cancer vs normal lung tissues) were performed.
Results: Analysis by real-time PCR and Western blotting revealed a significantly higher expression of GPER at
both mRNA and protein levels in human non small cell lung cancer cell (NSCLC) lines relative to immortalized
normal lung bronchial epithelial cells (HBECs). The virally immortalized human small airway epithelial cell line
HPL1D showed higher expression than HBECs and similar expression to NSCLC cells. Immunohistochemical
analysis of tissue sections of murine lung adenomas as well as human lung adenocarcinomas, squamous cell
carcinomas and non-small cell lung carcinomas showed consistently higher expression of GPER in the tumor
relative to the surrounding non-tumor tissue.
Conclusion: The results from this study demonstrate increased GPER expression in lung cancer cells and tumors
compared to normal lung. Further evaluation of the function and regulation of GPER will be necessary to
determine if GPER is a marker of lung cancer progression.
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Lung cancer is the leading cause of cancer deaths in
United State of America both in men and women [1].
Although controversial, some epidemiologic data indi-
cate that women have a higher risk of lung adenocarcin-
oma, a type of non-small cell lung cancer (NSCLC),
compared to men, independent of smoking status [2,3].
One recent study reported reduced risk of lung cancer
mortality in breast cancer patients, who were taking
antiestrogens [4]. This study also found that women* Correspondence: jvrao001@louisville.edu
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reproduction in any medium, provided the ortaking antiestrogens had a significant lower risk of devel-
oping lung cancer [4]. While it is known that estrogens in-
duce maturation of normal lung tissue [5,6], their role in
lung cancer initiation and progression remains unclear.
Estrogens regulate a wide variety of biological pro-
cesses including differentiation, cell proliferation, apop-
tosis, inflammation and metabolism primarily by binding
to two receptors: ERα and ERβ (ERs will refer to both
subtypes) [7-12]. ERα and ERβ belong to the nuclear re-
ceptor superfamily of ligand-activated DNA binding
transcription factors (reviewed in [13]). The classical
mechanism of E2 action involves binding to ERs to form
homo- or hetero- dimers followed by direct binding to
estrogen response elements (ERE) or tethering to other. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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regulatory regions of target genes [14]. The resulting re-
cruitment of co-activators and chromatin remodeling com-
plexes alters gene transcription leading to physiological
responses within hours following E2 exposure. Estrogens
also promote various types of cancers including breast can-
cer and ablation of estrogen synthesis or ER activities are
effective treatments to prevent disease recurrence [15].
ERα and ERβ proteins are expressed in primary lung
tumors (reviewed in [5]). In contrast to breast cancer, ERβ
levels are ~ twice that of ERα levels in lung cancers [16,17].
It was also reported that NSCLC cells express ERα and ERβ
and respond transcriptionally to E2 [18-22]. In addition to
the classical genomic mechanism of estrogen action, numer-
ous studies have demonstrated that E2 rapidly (in < 5 min.)
activates plasma membrane initiated signaling cascades
through G-Protein dependent pathways, including release
of intracellular calcium, IP3 accumulation, cAMP produc-
tion, and MAPK activation [23-26]. Both ERα [27,28] and
ERβ [29] appear to localize with protein kinases and other
proteins in ‘signalosome’ complexes in caveolae in the
plasma membrane in a cell type-dependent manner. In this
context, the non-genomic E2-ERβ dependent signaling and
cooperation between β1adrenergic receptor and ERβ sig-
naling pathways may contribute to the smoking-associated
lung carcinoma progression in women [30]. There is also
considerable evidence for a role for E2 activation of
membrane-associated ER crosstalk with epidermal growth
factor receptor (EGFR) (reviewed in [10,31-38]).
GPR30/GPER (also known as DRY12, FEG-1, LERGU,
LyGPR, CMKRL2, LERGU2 and GPCR-Br) was first
identified as a GPCR involved in membrane-mediated
E2- signaling [39-42]. The precise role of GPER, its intra-
cellular location, and role in mediating estrogen function
remains controversial [27,43-46]. GPER was reported to
bind E2 with high affinity (Kd = 3–7 nM) and to activate
multiple intracellular signal transduction pathways, e.g.,
calcium mobilization, cAMP production, PI3K activation
and ERK1/2 activation in a G-protein dependent man-
ner. Northern blot, real time PCR, and immunohisto-
chemistry (IHC) analyses showed that GPER is expressed
in placenta, heart, lung, liver, prostate, bone marrow and
fetal liver [47], but a complete atlas of GPER protein ex-
pression and its functional roles are yet to be established.
Here, we report for first time, the expression patterns of
GPER in lung cancer cell lines and human lung cancer tis-
sues. The results from our studies indicate that the ex-
pression of GPER is elevated in lung tumors compared to
normal/adjacent lung tissues.
Results
Expression of GPER in lung cancer cell lines
Although at the time of its cloning, GPER was shown to be
expressed in normal human lung by Northern blot [48], itsexpression in lung cancer cell lines or lung tumors has not
been examined. The mRNA levels of GPER were deter-
mined in human NSCLC, lung adenocarcinoma cell lines:
A549, NCI-H23, NCI-H1299, NCI-H1792, NCI-H1395,
NCI-H1435, NCI-H1793, NCI-H1944, NCI-H2073 (all pur-
chased from ATCC); immortalized, but not transformed,
human bronchial epithelial lung cell lines obtained
from Dr. John D. Minna, UT Southwestern: HBEC3-KT,
HBEC2-E and HBEC2-KT [49]; the SV40-immortalized
human small airway epithelial cell line HPL1D, derived
from a female non-smoker without lung cancer [50],
was kindly provided to us by Dr. T. Takahashi (Center
of Neurological Diseases and Cancer, Nagoya Univer-
sity Graduate School of Medicine, Nagoya, Japan) and
Dr. Hildegard M. Schuller, Department of Pathobiology,
College of Veterinary Medicine, University of Tennessee,
Knoxville, TN) [51,52]; and the human MCF-7 breast
cancer cell line was obtained from ATCC as a positive
control for GPER [44]. Both semi-quantitative PCR
(Additional file 1: Figure S1) and real time quantitative
PCR (Figure 1A) were performed. These results pro-
vide the first evidence of GPER expression in human
lung adenocarcinoma cell lines.
Increased expression of GPER in lung cancer lines
To more accurately examine the mRNA levels of GPER,
quantitative real time PCR was performed on lung can-
cer and normal HBEC lines. As shown in Figure 1A and
Table 1, the expression level of GPER is higher in most
of the lung cancer cell lines compared to HBECs and
HPL1D cells. In 12 lung cancer cell lines tested, GPER
relative overexpression ranged from 2 to 10 fold com-
pared to normal HBECs (Table 1). The protein levels of
GPER in representative lung adenocarcinoma cell lines,
HBEC2-KT, HBEC3-KT, HPL1D, and in MCF-7 breast
cancer cells were determined by Western blots using
three different antibodies obtained from different com-
mercial sources (Figure 1B-D). Each of the antibodies
recognized a number of bands that have, in the case of
Novus NBP1-31239 and NLS 4271, been demonstrated
by using blocking peptides to be specific and are consid-
ered to be various glycosylated forms of GPER [53], or
to indicate homodimerization or interaction with other
proteins in detergent-resistant complexes [54-56]. Sur-
prisingly, the expression of GPER mRNA and protein
are not concordant, nor was there concordance between
GPER levels with the three antibodies tested in each cell
line, although consistency was observed in H1793 cells
for MCF-7 and T47D cells with the 2 Novus antibodies,
between the NLS4272 and SC-48524 for H23 cells.
Nonetheless, these data for the first time demonstrate
GPER expression in lung adenocarcinoma cells and nor-
mal lung cells and suggest that the levels of GPER ex-
pression are, on average, higher in the NSCLC cells
Table 1 GPER mRNA fold level change in lung cancer cell lines compared to normal lung epithelial cells
Cell line Sex of patient Smoker/non-smoker Level of GPR30
HBEC 3ET as baseline HBEC 2E as baseline HBEC 2KT as baseline
HBEC 3ET 1.00 0.96 1.74
HBEC 2E 1.04 1.00 1.81
HBEC 2KT 0.57 0.55 1.00
HPL1D Female Nonsmoker no lung cancer 4.06 1.19 0.74
A549 Male Unknown 0.29 0.28 0.5
NCI-H1792 Male Smoker 5.15 4.96 8.99
NCI-H23 Male Smoker 1.97 1.89 3.43
NCI-H1299 Male Smoker 4.67 4.50 8.15
NCI-H2073 Female Smoker 1.09 1.05 1.90
NCI-H1395 Female Smoker 4.80 4.63 8.38
NCI-H1944 Female Smoker 2.56 2.46 4.46
NCI-H1793 Female Non-Smoker 1.34 1.29 2.34
MCF7 Female Unknown 9.74 9.38 16.98
Figure 1 GPER/GPR30 expression in normal lung cell lines and lung adenocarcinoma cell lines. A) The expression of GPER was determined
by realtime quantitative PCR in each of the normal lung cell lines (open bars), lung adenocarcinoma cell lines (grey bars), and MCF-7 human
breast cancer cells (black bar). Values are the average of 4–6 biological replicates ± SEM. B-D) Representative western blot analysis of GPER/GPR30
expression in the indicted cell lines. 30 μg of whole cell extract (WCE) were separated on 10% SDS PAGE gels with MW marker migration
indicated at the left of each blot. The diagrams at the top of B-C, and D indicate the region of GPER recognized by the 3 different polyclonal
antibodies used: B) Novus NBP-1-31239, C) Novus NLS4271; D) Santa Cruz sc-4854-R. The MW of GPR30 is estimated to be 42 kDa, but higher MW
sizes have been reported due to glycosylation and interaction with other proteins. Bands are identified as glycosylated and nonglycosylated
based on reports cited in the text, but could include interaction with other proteins. For each GPER western, the membrane was stripped and
reprobed for β-actin as a loading control. Quantitation of GPER was evaluated by summing all immunoreactive bands and dividing by β-actin,
then normalizing to HBEC2-KT in each blot. Panel E is a summary of all westerns (not all westerns are shown) with each antibody. For Westerns
with NBP1-31239 and sc-48524, values are the mean ± SEM from 3 separate blots using different WCE.
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It is possible that the discordant findings between tran-
script and protein levels result from altered splicing or
mutations in the C-terminus of GPER, but this idea
requires further investigation. Three SNPs were described
in GPER with one resulting in a single Pro16Leu aa
change within the coding region [57]. Additionally, it is
also possible that specificity/affinity as well as quality
of these GPER antibodies may vary between different
sources and the impact of glycosylation and other
post-transcriptional modifications on antibody inter-
action is also an issue.
Elevated levels of GPER expression in mouse and human
lung cancer tissues
The expression pattern of GPER in normal and lung
cancer tissues was examined using Immunohistochemis-
try (IHC) staining.
a)Mouse lung tumors: The IHC was performed to
determine the expression of GPER and proliferating
cell nuclear antigen (PCNA) in paraffin embedded
tissue sections of mouse lung tumors. The mouse lung
tumors were induced using 3-methylcholanthrene
-butylated hydroxytoluene (MCA-BHT). The
representative H&E stained (Figure 2A) and IHC
images of mouse lung tumor sections are shown
(Figure 2B-D). The isotype control antibody showed
no positive staining (Figure 2C). The expression ofFigure 2 Expression of GPER/GPR30 in mouse lung tumors. (A) IHC an
lungs were stained with H & E (A), GPR30 C-terminal antibody (Novus Biol
(D) using standard IHC protocols.GPER and PCNA staining appear to localize to the
same regions (Figure 2D) suggesting that GPER is
overexpressed in proliferating tumor cells.
b)Human lung tumors: The human multiple lung
cancer tissue arrays with unmatched normal adjacent
tissues (US Biomax Inc #LC242 (10 cases) and
LC1005 (77 cases) were used to determine the
expression of GPER patterns. A human breast cancer
test tissue array was used with self-matching or
unmatched normal adjacent tissues (US Biomax Inc
#BR241) as a positive control. The representative
lung tumor shown in Figure 3A is from male (age
57) and classified as adenocarcinoma, Grade II and
malignant tumor. This tissue micro array LC242
represents 10 cases of lung tumor with 2 non-
neoplastic tissue (duplicated core in 1.5 mm size per
case) sections. The expression of GPER in another
TMA (LC1005), containing 77 cases of lung cancer
tissues along with normal (8 cases) and cancer
adjacent tissues (42 cases) were also analyzed. The
representative images of H and E and IHC analysis of
GPER expression in different types of lung cancers
are shown in Figure 3A-D along with normal
adjacent lung tissues. The positive staining for GPER
in human breast cancer (Infiltrating ductal
carcinoma not otherwise specified (NOS), Grade II,
malignant) is much stronger compared to non-tumor
regions of matched adjacent tissues, which served as
positive control in these IHC studies (Figure 3E-F).alyses of mouse lung cancer (induced with MCA-BHT). The whole
ogicals, 10 μg/ml) (B) along with isotype control (C) and PCNA
Figure 3 GPER/GPR30 expression in human lung and breast tumors. The TMA slides, ‘Multiple lung cancer test array with unmatched
normal adjacent tissue’ (US BioMax Inc, #LC242) and ‘human breast cancer test tissue array with self-matching or unmatched normal adjacent
tissues’ (US Biomax Inc #BR241) were stained with H&E and anti-GPR30 (10 μg/ml). (A-B). The representative tissue spot/core images of Hand
E (A) and GPR30 (B) staining for lung cancer (adenocarcinoma) are shown. (C-D). The representative normal lung tissue for H and E (C) and
GPR30 staining (D) are shown. (E-F) The breast cancer TMA slides were stained with H&E and anti-GPR30 as a positive control for GPR30
expression. The images were collected at 200X magnification using Aperio image scope. The scale bars indicate 100 μm.
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cell carcinoma and large cell carcinoma (Figures 4
and 5). The overall results suggest that the GPER is
overexpressed in lung cancer tissues compared to
normal/adjacent lung tissues.
c) Scoring of GPER staining: The scoring of the GPER
staining was performed by two independent
pathologists. The scoring pattern for GPER staining
as follows. Score 0, negative staining for all cells;
score 1+, weakly positive for cytosolic staining in
<10% of cells; score 2+, moderate to strong positive
staining covering between 10 to 50% of cells and
score 3+, strongly positive staining including >50%
cells (Figure 6). All the scoring was done in a blinded
manner regarding tumor type/stage data. The
comparison between two non-parametric groups was
done using Mann–Whitney U test. The GPER scoreswere compared between the cancer tissues and
cancer-adjacent tissue/normal lung tissue. The IHC
scores were grouped into two groups, negative or
weakly positive (0 and 1+) and moderately to
strongly positive (2+ and 3+) (Table 2). IHC
quantification (Figure 6 and Table 2) suggests that
GPER is significantly overexpressed in lung tumors
compared to either normal lung or cancer-adjacent
tissues. GPER positive staining (moderate intensity)
was observed on the alveolar macrophages in the
normal lungs. We did not observe any detectable
GPER IHC positive staining in the normal lung
epithelium. GPER is significantly overexpressed
(2–3 score) in > 80% the adenocarcinomas
(p<0.0001), 75% in large cell carcinoma (p<0.0001)
and 60% in squamous cell carcinoma (p<0.0001).
Overall, > 76% of all lung cancer tissues showed
Figure 4 GPER/GPR30 expression in human lung tumors. The TMA slides were stained with H&E and anti-GPR30. The representative tissue
spots/cores for normal (A) and squamous cell carcinoma (B) are shown. The left panels represent H and E staining of normal lung (A) and
squamous cell carcinoma (B) and right panels representGPR30 IHC staining at 46X (scale bar 500 μm) and 400X (scale bar 50 μm) magnification
The images were collected using Aperio imagescope.
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normal lung tissues/adjacent tissues (score 2 to 3)
showed any detectable GPER expression. We conclude
that GPER expression is increased in lung cancer.
Discussion
GPER is an E2 binding, G-protein coupled membrane re-
ceptor [39-42,58] that was reported to be overexpressed
in breast [40,59] endometrial [60,61], ovarian [62] and
thyroid cancers [63]. The results presented here extendthese observations to show that different types of lung
cancers including adenocarcinomas, squamous cell car-
cinoma and large cell carcinomas express higher GPER
than normal lung tissue.
Here, we demonstrate for the first time that GPER is
overexpressed in lung tumors and lung adenocarcinoma
cell lines relative to normal lung and immortalized nor-
mal lung cell lines, although the expression of GPER
transcript in HPL1D cells is higher than HBECs. GPER
has been postulated to be involved in E2-activation of
Figure 5 GPER/GPR30 expression in human large cell lung carcinoma. The TMA stained with H&E and anti-GPR30. The representative tissue
images of stained with H and E (A) and anti-GPR30 (B) of large cell carcinoma are shown at 200X and 400X magnifications. The scale bar for
200X is 100 μm and 400X is 50 μm. The images were collected using Aperio imagescope.
Figure 6 Scoring of GPER/GPR30 expression in lung tumors. The scoring pattern for GPR30 staining as follows. Score 0, negative staining for
all cells; score 1+, weakly positive for cytosolic staining in <10% of cells; score 2+, moderate to strong positive staining covering between 10 to
50% of cells and score 3+, strongly positive staining including >50% cells. The images are shown at 200X magnification and the scale bar
indicates 100μm. The images were collected using Aperio imagescope.
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Table 2 GPER IHC scoring in tissue microarrays




Adenocarcinoma 2 of 15 (13.3%) 13 of 15 (86.7%) P<0.0001 P=0.0007
Squamous cell carcinoma 13 of 33 (40%) 20 of 33 (60.0%) P<0.0001 P= 0.0024
Large cell carcinoma 2 of 8 (25%) 6 of 8 (75%) P<0.0001 P=0.0011
Metastatic adenocarcinoma 1 of 6 (16.7%)) 5 of 6 (83.3%) P=0.0002 P=0.0013
Cancer adjacent lung tissue 41 of 42 (97.6%) 1 of 42 (2.4%) No significant
Normal lung tissue 8 of 8 (100%) 0 of 8 (0) No significant
The scoring pattern for GPR30 staining as follows. Score 0, negative staining for all cells; score 1+, weakly positive for cytosolic staining in <10% of cells; score 2+,
moderate to strong positive staining covering between 10 to 50% of cells and score 3+, strongly positive staining including >50% cells.
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expression and tumor progression and increased tumor
size in breast cancer patients [40]. Recently, GPER overex-
pression was reported to be independent of ERα expres-
sion in breast cancer patient samples, indicating the
importance of GPER in ERα negative tumors [64]. GPER
and EGFR expression were correlated in endometrial
adenocarcinoma [60]. Further, overexpression of GPER in
advanced stage endometrial adenocarcinoma correlated
with poor survival [60]. Other studies also suggest
increased GPER in breast, ovarian and endometrial can-
cers correlates with disease severity and reduced survival
[40,59,60,62,65]. These results are in agreement with stud-
ies demonstrating association of GPER overexpression in
other cancers [40,59,60,62,64,65], although the scoring
patterns and correlation of expression levels to disease
state may vary among these studies. A limitation of our
study is that the average GPER staining scores among
different lung cancer grades (I (10 cases), II (30 cases),
III (16 cases)) were not significantly different. One
other limitation of the current study is that we cannot
conclude at this time whether GPER overexpression is
cause or consequence of cancer. It is also possible that
overexpression of GPER in lung cancers may reflect a
defense mechanism to counteract excessive prolifera-
tion. Indeed, a recent report by Krakstad et al. showed
that loss of GPER in ERα-positive endometrial cancers
is associated with poor prognosis [66]. Another study
showed that the GPER agonist G-1 inhibited E2-induced
uterine epithelial cell proliferation in mice by repressing
MAPK activation, indicating that GPER effects are tissue
specific [67]. Because our studies were performed on com-
mercial TMAs, the results cannot be extrapolated to cor-
relate GPER expression levels to disease outcomes. Clearly,
this is a next logical step in light of the novel findings.
We observed no differences in GPER expression be-
tween adenocarcinoma cell lines or tumors from male
and female patients, similar to the previous findings of
no difference in ERα or ERβ expression in NSCLC cells
and tumors based on gender [20,68-70]. In Westernblots, rather than rely on one GPER antibody in our
study, we used 3 different commercial antibodies to de-
termine the correlation between mRNA and protein
levels. It is indeed evident from our Western blot data that
GPER appears to have different MW forms, likely due to
glycosylation [53], dimerization [54,55], and interaction
with other membrane proteins [56], and levels in the lung
adenocarcinoma cell lines. More trivial explanations for
the different staining patterns of GPER in Western blots
may be due to differential purity/affinity of the three
GPER antibodies as well as their capacity to bind to sec-
ondary antibodies. It will be important to determine the
nature of these forms by proteomic analysis and gene se-
quencing to evaluate their biological significance.
The role of GPER as an E2 membrane receptor is con-
troversial and its functional significance is unclear. Some
reports suggest that GPER is not an estrogen receptor
because it does not bind E2 and thus still consider it as
an orphan GPCR [27,71-73]. The recent identification of
estrogen receptor splice variant called ERα36 adds one
more layer of complexity to estrogen biology and the role
of GPER [72]. ERα36 was reported to be responsible for
E2 induced non-genomic signaling rather than GPER [72].
Mechanism-based studies showed that GPER transac-
tivates EGFR in breast cancer cells [38,39,74-76] as well
as in thyroid, endometrial and ovarian cancer cell lines
[61,63,77,78]. Inhibitors of EGFR tyrosine kinase (gefiti-
nib) and ER (fulvestrant, ICI 182,780) were reported to
synergize their anti-proliferative effects in NSCLC [19].
Given the importance of EGFR signaling as a therapeutic
target in lung cancer [79,80], further examination of the
effect of EGF, heregulin, and amphiregulin on GPER ex-
pression and function in lung cancer may provide new
insights into resistance to EGFR inhibitors and or how
estrogens stimulate lung cancer.
Conclusion
In conclusion, the data presented in this manuscript
demonstrate that GPER expression is higher in lung
tumors compared to normal lung tissue. While it is not
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consequence from lung cancer progression. Functional
analysis of the effect of GPER expression will facilitate
further delineation of the role of GPER in lung cancer.Methods
Cell lines and mouse lung tissues
Normal human bronchial epithelial cell lines HBEC2-E
HBEC2-KT, and HBEC3-KT were kindly provided by
Dr. John D. Minna [49]. HPL1D, an SV40-immortalized
human small airway epithelial cell line derived from a fe-
male non-smoker without lung cancer [50] was kindly
provided to us by Dr. T. Takahashi (Center of Neuro-
logical Diseases and Cancer, Nagoya University Graduate
School of Medicine, Nagoya, Japan) and Dr. Hildegard M.
Schuller, Department of Pathobiology, College of Veterin-
ary Medicine, University of Tennessee, Knoxville, TN)
[51,52]. Human lung adenocarcinoma cell lines A549,
NCI-H1435, NCI-H1395, NCI-H1944, NCI-H1792, NCI-
H1793, NCI-H2073, NCI-H23, and NCI-H1299 and
human breast cancer cell lines MCF-7 and T47D were
purchased from ATCC (Manassas, VA, USA) and used
within 10 passages from the time of purchase from ATCC.
The growth conditions for each of these lines were
described previously [21,22]. Cell culture media supplies
obtained either from Invitrogen (Carlsbad, CA, USA) or
Mediatech, Inc. (Manassas, VA, USA). All the experimen-
tal protocols, usage of human cell lines and chemicals
have been approved by the Institutional Biosafety Com-
mittee (IBC) at University of Louisville. The mouse lung
tumor tissue sections were obtained from MCA-BHT
induced lung cancer mouse model (Elangovan et al un-
published). All the animal experimental protocols have
been approved by the Institutional Animal Care and Use
Committee (IACUC) at University of Louisville.RNA isolation, cDNA synthesis, RT PCR
Total RNA was isolated using Qiagen RNAasy mini kit
(Qiagen, Valencia, CA, USA) according to manufactures’
protocols and as described [21,22]. The isolated total
RNA was treated with DNAse followed by synthesis of
cDNA by reverse transcriptase (Applied Biosystems,
Carlsbad, CA, USA). The similar reaction was also per-
formed without reverse transcriptase as a control. The
regular PCR reaction with Mango Taq Polymerase was
performed on the above cDNA samples as templates to
detect the presence of GPER using specific primers (FP
50 AGTCGG ATGTGAGGTTCAG 30 and RP 50 TC
TGTGT GAGGAGTGCAAG 30) for GPER and Human
ribosomal phosphor-protein (36B4) as reference marker
[76]. The PCR was also performed on the cDNA reac-
tion mix that did not contain reverse transcriptase as a
negative control.Real time PCR
For quantitative real-time PCR, 1 μg of total RNA was
reverse transcribed in 50 μl reaction using TaqMan re-
verse transcription reagents (Applied Biosystems) using
random hexamer primers. 2 μl of cDNA and the 1 μM
real time PCR primers were used in a final 20 μl qPCR
reaction with ‘power SYBR-green master mix’ (Applied
Biosystems). The sequences of the real time primers as
follows: hGPER FP: 50 AGTCGGATGTGAGGTTCAG
30; hGPER RP: 50 TCTGTGTGAGGAGTGCAAG 30
[81]; h36B4 FP: 50 CTCAACATCTCCCCCTTCTC 3;
h36B4 RP: 50 CAAATCCCATATCCTCGTCC 30. Real
time qPCR was performed in ABI-Prism 7900 sequence
detect system (Applied Biosystems). Expression of the
target genes was normalized to ribosomal phosphopro-
tein (36B4) and displayed as fold change relative to the
wild type sample.
Western blots
The cell lysates were prepared using RIPA plus buffer.
10 μg of total lysates were loaded on to SDS PAGE gels
and detected using antibodies anti-GPER antibodies
(Novus Biologicals, Littleton, CO, USA), Santa Cruz Bio-
technology Inc (Santa Cruz, CA, USA). The membrane
was stripped and used for beta-actin detection with anti-
beta-actin-HRP antibody (Santa Cruz Biotechnology
Inc.). The GPER antibodies obtained from Novus Biologi-
cals were raised against synthetic peptide contain a se-
quence corresponding to a region within amino acids 244
and 306 (NBP1 31239) and second one against the syn-
thetic peptide [KLH conjugated] made to the C-terminal
of human GPER (NLS 4272). Another antibody from
Santa Cruz Biotechnology Inc. is raised against internal re-
gion of human GPER. β-Actin-HRP antibody obtained
from Santa Cruz Biotechnology Inc.
Immunohistochemistry
The paraffin embedded lung tumor tissue sections were
routinely deparaffinized and endogenous peroxidase was
quenched with 3% H2O2 in 1XPBS. The epitope retrieval
was performed by heating for 30 min in sodium citrate
buffer (pH6.0) in a water bath at 95-100°C. The anti-
GPER antibody (Novus Biologicals) and isotype control
used as primary antibodies. After 1 hr incubation with
the primary antibody at room temperature, the slides
were washed twice with 1XPBS (5 min per wash), and
then incubated with the secondary antibody solution for
30 min at room temperature. Visualization of GPER
positive cells was done by using ABC staining system
(Santa Cruz Biotechnology). Negative controls for all
staining were done by omitting primary antibodies as
well as use of isotype control antibodies. The sections
were evaluated by Aperio Imagescope and quantified the
number of positive cells at 200x magnification.
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Human lung cancer (LC 242, LC1005) and breast cancer
(BR 241) tissue microarrays used in this study were pur-
chased from US Biomax Inc. (Rockville, MD, USA).
Scoring of GPER expression
The scoring of the GPER staining was performed by
Swarupa Gadre, M.D., pathologist, U of L and recon-
firmed by an independent pathologist, A. Bennett Jensen,
M.D., Brown Cancer Center, U of L. The scoring pattern
for GPER staining as follows: Score 0, negative staining
for all cells; score 1+, weakly positive for cytosolic stain-
ing in <10% of cells; score 2+, moderate to strong posi-
tive staining covering between 10 to 50% of cells and
score 3+, strongly positive staining including >50% cells.
For statistical purposes IHC scores were grouped into
two groups, negative or weakly positive (0 and 1+) and
moderately to strongly positive (2+ and 3+). All the scor-
ing was done in a blinded manner to tumor type/stage
data of tissue microarray. The pairwise comparisons
were performed (cancer vs adjacent tissues as well as can-
cer vs normal lung tissues) using Mann–Whitney U test
in Graphpad Prism software.
Additional file
Additional file 1: Figure S1. The semi-quantitative PCR of GPER
(GPR30) in lung adenocarcinoma cells. RNA was isolated from each of the
indicated cell lines and the cDNA was prepared as described in methods
section. The semi-quantitative was performed using GPR30 primers and
human ribosomal phosphoprotein (36B4) as reference as described
Methods.
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